Clinical Trial Update: Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating prasterone (DHEA) for hypoactive sexual desire disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoactive Sexual Desire Disorder

Drugs mentioned

• prasterone (DHEA) (prasterone (DHEA))

Snippet

Sponsor: EndoCeutics Inc. | Conditions: Hypoactive Sexual Desire Disorder (HSDD) | Phase 3 | Status: WITHDRAWN